Safest Intranasal Corticosteroid Use in Pregnancy

Choice of Intranasal Corticosteroid

• Budesonide is the preferred first‑line intranasal corticosteroid for pregnant patients because it is classified as FDA Pregnancy Category B and is supported by the largest human safety dataset (> 6,600 pregnancies). This recommendation is based on data from the Journal of Allergy and Clinical Immunology. 1

• If a patient is already using any intranasal corticosteroid (fluticasone, mometasone, budesonide, or beclomethasone) before conception, therapy should be continued unchanged; there is no meaningful difference in efficacy or safety among agents, and switching may disrupt symptom control. Evidence from multiple 2008 studies in the Journal of Allergy and Clinical Immunology supports this approach. 1

• When initiating therapy during pregnancy, budesonide should be started first, given its Category B status and extensive safety record. Alternative agents such as mometasone and fluticasone propionate are acceptable at recommended doses despite being Category C, because safety data are reassuring. These alternatives are supported by a 2020 Rhinology review. 5

• Beclomethasone may also be used; existing studies have not identified convincing evidence of congenital defects associated with its use. 1

Safety Evidence

• A comprehensive meta‑analysis (Journal of Allergy and Clinical Immunology, 2008) found no increased risk of major malformations, preterm delivery, low birth weight, or pregnancy‑induced hypertension among pregnant women using intranasal corticosteroids. 1

• Systemic absorption of intranasal corticosteroids is negligible compared to oral formulations, allowing safety conclusions from inhaled corticosteroid data to be applied conservatively to the intranasal route. Pharmacologic studies demonstrate markedly lower systemic exposure after intranasal versus oral administration. (Journal of Allergy and Clinical Immunology, 2008) 2

Dosing Recommendations

• Prescribe the lowest effective dose that controls symptoms throughout all trimesters, adhering to the minimum effective dose principle endorsed by the 2008 Journal of Allergy and Clinical Immunology and the 2020 Rhinology guideline. 1

• Do not exceed the manufacturer‑specified maximum daily dose; exceeding this limit offers no additional benefit and may increase systemic exposure. (Praxis Medical Insights, 2026) 4

• When possible, taper to the minimum dose needed for symptom control rather than stopping therapy abruptly, to maintain disease control and avoid rebound worsening. (Journal of Allergy and Clinical Immunology, 2008) 2

Comparative Safety Ranking

Risks of Oral Corticosteroids and Oral Decongestants

• Oral corticosteroids are associated with serious fetal risks, especially in the first trimester, including increased incidence of cleft lip/palate, preeclampsia, preterm delivery, low birth weight, and gestational diabetes. These risks are documented in the 2020 Rhinology guideline. 5

• Oral decongestants (pseudoephedrine, phenylephrine) should be avoided in the first trimester because epidemiologic data link them to higher rates of congenital malformations such as gastroschisis (Journal of Allergy and Clinical Immunology, 2008). 1

Consultation, Patient Communication, and Breastfeeding

• Obstetric consultation is recommended when initiating intranasal corticosteroid therapy, particularly for complex cases or when oral corticosteroids might be considered after the first trimester. Guidance from Rhinology (2020) and Praxis Medical Insights (2025) supports this collaborative approach. 5

• Clinicians should discuss the benefits and potential risks with the patient to ensure informed decision‑making; this shared‑decision model is endorsed by the 2008 Journal of Allergy and Clinical Immunology. 2

• Intranasal corticosteroids are compatible with breastfeeding because systemic absorption is minimal, resulting in negligible drug transfer to breast milk (Praxis Medical Insights, 2026). 4